Stay updated on GT90001+Nivolumab in Metastatic HCC Clinical Trial
Sign up to get notified when there's something new on the GT90001+Nivolumab in Metastatic HCC Clinical Trial page.

Latest updates to the GT90001+Nivolumab in Metastatic HCC Clinical Trial page
- ChecktodayChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check15 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference2%
- Check22 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check44 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check58 days agoChange DetectedThe webpage has undergone significant changes in the description of a clinical study for metastatic hepatocellular carcinoma (HCC), including the removal of detailed study protocols and inclusion/exclusion criteria, while retaining the study's title and drug combination information.SummaryDifference37%
Stay in the know with updates to GT90001+Nivolumab in Metastatic HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GT90001+Nivolumab in Metastatic HCC Clinical Trial page.